{"id":"W2563401770","doi":"10.1371/journal.pone.0167906","title":"Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"McGill University; Bayer Corporation","keywords":"Medicine; Vinorelbine; Sorafenib; Metastatic breast cancer; Internal medicine; Discontinuation; Neutropenia; Breast cancer; Oncology; Cohort; Surgery; Cancer; Gastroenterology; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001288556,0.001947958,0.002311349,0.0005514362,0.0005037133,0.001043277,0.001072441,0.001272403,0.004005856],"category_scores_gemma":[0.0009251706,0.0006894597,0.0009588731,0.0004997163,0.0009946171,0.0007277816,0.0003671196,0.003489549,0.0008639721],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00115254,"about_ca_system_score_gemma":0.001972854,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001178112,"about_ca_topic_score_gemma":0.002984219,"domain_scores_codex":[0.99962,0.0001630818,0.00001760079,0.00006563299,0.00003837469,0.00009531564],"domain_scores_gemma":[0.9992421,0.0001051949,0.0001203417,0.00006293443,0.00004043953,0.0004291295],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7065737,0.1262215,0.004994461,0.00104394,0.001505356,0.0005402739,0.0003273296,0.004038517,0.05413609,0.000375835,0.006466494,0.09377662],"study_design_scores_gemma":[0.6536857,0.333411,0.005076696,0.00003197338,0.0002458903,0.0002926692,0.00002875998,0.001325411,0.003751596,0.0001519561,0.00197677,0.00002163716],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915867,0.001854742,0.0005096953,0.0007431546,0.0002090382,0.002685089,0.0008305302,0.0001233548,0.001457804],"genre_scores_gemma":[0.9868198,0.001853247,0.00178172,0.0007804632,0.0002718063,0.003057156,0.002275689,0.00003451624,0.003125522],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004005856,"threshold_uncertainty_score":0.01340091,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05820120234686946,"score_gpt":0.3504323244064289,"score_spread":0.2922311220595594,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}